These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 11072283)

  • 21. The VA HDL intervention trial: clinical implications.
    Rubins HB; Collins D; Robins SJ
    Eur Heart J; 2000 Jul; 21(14):1113-5. PubMed ID: 10924289
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapy and clinical trials.
    Curr Opin Lipidol; 1995 Dec; 6(6):B77-82. PubMed ID: 8750254
    [No Abstract]   [Full Text] [Related]  

  • 23. [Eiconol effects on hemocoagulation in coronary heart disease patients].
    Dzhanashiia PK; Panchenko VM; Nazlukhanian SO; Chernova GI; Liutova LV; Semenov VA; Korneenkov VK; Perekrestova EI; Nurmukhamedov SA; Andreenko GI
    Klin Med (Mosk); 1997; 75(10):55-7. PubMed ID: 9490343
    [No Abstract]   [Full Text] [Related]  

  • 24. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
    Brotons Cuixart C; Maiques Galán A
    Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
    [No Abstract]   [Full Text] [Related]  

  • 25. Strategies for optimizing lipid treatment outcomes.
    Spellman CW
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S12-5. PubMed ID: 12572625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronary heart disease in HIV-infected persons.
    Glesby MJ
    AIDS Read; 2003 Apr; 13(4 Suppl):S15-9. PubMed ID: 12762289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dyslipidemia in the elderly].
    Lasses y Ojeda LA; Gutiérrez JL; Salazar E
    Arch Cardiol Mex; 2004; 74(4):315-26. PubMed ID: 15709510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The risk and treatment of hyperlipoproteinemias].
    Alzamora P; Alegría E; Iglesias I
    Rev Med Univ Navarra; 1990; 34(1):29-30, 32-5, 37-40. PubMed ID: 2096448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of hyperlipidaemia: postscript.
    Sum CF; Tan CE; Chew LS
    Singapore Med J; 1995 Oct; 36(5):538. PubMed ID: 8882543
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thiadenol in the short-term treatment of patients with blood lipid disorders].
    Di Stefano F; Patane S; Gatto A
    Minerva Med; 1980 Mar; 71(8):567-74. PubMed ID: 7360386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Editorial on CHD.
    Riesen WF
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S1-2. PubMed ID: 9044998
    [No Abstract]   [Full Text] [Related]  

  • 33. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of atherosclerosis with hypolipidemic and antiuricemic agents].
    Plastinina RA; Oleĭnik NA; Valeeva RM; Pavlova TN
    Sov Med; 1984; (1):83-7. PubMed ID: 6701660
    [No Abstract]   [Full Text] [Related]  

  • 35. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Also elderly patients with hyperlipidemia and coronary disease need lipid lowering agents].
    Hellénius ML
    Lakartidningen; 2001 Sep; 98(39):4188-90. PubMed ID: 11680152
    [No Abstract]   [Full Text] [Related]  

  • 38. [Lipids and acute coronary syndromes].
    Stejfa M
    Vnitr Lek; 2000 Sep; 46(9):520-5. PubMed ID: 11344644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [J-LIT [Japan Lipid Intervention Trial]].
    Itakura H
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():462-8. PubMed ID: 11347114
    [No Abstract]   [Full Text] [Related]  

  • 40. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
    Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
    Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.